Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (141-150 of 247) with videos related to

Pageof 25
Sort By:
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Nature Communications|January 9, 2026
Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adultsLeonie Mayer, Anahita Fathi, Hanna-Marie Weichel, et al.
Molecular Oncology|June 16, 2017
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insightsRodrigo Dienstmann, Elena Elez, Guillem Argiles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and gliomaJordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.
Journal for Immunotherapy of Cancer|August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapyBettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in <i>BRCA1</i> and <i>BRCA2</i> by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulatorsJiakai Hou, Yunfei Wang, Leilei Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Pageof 25

Showing results (141-150 of 247) with videos related to

Sort By:
Pageof 25
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Nature Communications|January 9, 2026
Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adultsLeonie Mayer, Anahita Fathi, Hanna-Marie Weichel, et al.
Molecular Oncology|June 16, 2017
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insightsRodrigo Dienstmann, Elena Elez, Guillem Argiles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and gliomaJordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.
Journal for Immunotherapy of Cancer|August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapyBettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in <i>BRCA1</i> and <i>BRCA2</i> by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulatorsJiakai Hou, Yunfei Wang, Leilei Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Pageof 25